US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist
  • 1.380
  • +0.150+12.20%
Close Feb 14 16:00 ET
  • 1.380
  • 0.0000.00%
Post 20:01 ET
113.92MMarket Cap-0.54P/E (TTM)

About Editas Medicine Company

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolEDIT
Company NameEditas Medicine
Listing DateFeb 3, 2016
Issue Price16.00
Founded2013
CEODr. Gilmore O’Neill, M.B.
MarketNASDAQ
Employees265
Fiscal Year Ends12-31
Address11 Hurley Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-401-9000
Websitehttp://www.editasmedicine.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Gilmore O’Neill, M.B.
  • Director, Chief Executive Officer and President
  • 2.39M
  • Erick J. Lucera, C.F.A.
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • 2.22M
  • Linda Burkly
  • Executive Vice President and Chief Scientific Officer
  • 1.54M
  • Bernadette M. Connaughton
  • Independent Director
  • 215.06K
  • Dr. Elliott M. Levy, M.D.
  • Independent Director
  • 264.88K
  • Dr. David T. Scadden, M.D.
  • Independent Director
  • 213.06K
  • Dr. Jessica Hopfield, PhD
  • Independent Director
  • 231.07K
  • Andrew J. Hirsch
  • Independent Director
  • 210.56K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!